Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4887MR)

This product GTTS-WQ4887MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4887MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15247MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ15305MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ11106MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ6493MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ2540MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ13627MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ12619MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ2120MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW